14348-22-2

Basic information

• Product Name: CNIDILIN
• Synonyms: CNIDILIN;4-[(3-Methyl-2-butenyl)oxy]-9-methoxy-7H-furo[3,2-g][1]benzopyran-7-one;5-(Isopentenyloxy)-8-methoxypsoralen;9-methoxy-4-[(3-methyl-2-butenyl)oxy]-7H-Furo[3,2-g][1]benzopyran-7-one;Isophellopterin;Knidilin
• CAS NO: 14348-22-2
• Molecular Formula: C17H16O5
• Molecular Weight: 300.31
• Mol File: 14348-22-2.mol
• Article Data: 2

Chemical Properties

• Melting Point: 117-118℃
• Appearance: /
• Density: 1.243
• CAS DataBase Reference: CNIDILIN(CAS DataBase Reference)
• NIST Chemistry Reference: CNIDILIN(14348-22-2)
• EPA Substance Registry System: CNIDILIN(14348-22-2)

Safety Data

• Hazardous Substances Data: 14348-22-2(Hazardous Substances Data)

Usage

Description

CNIDILIN, a significant bioactive compound found in Radix Angelicae dahuricae, is known for its medicinal properties and potential therapeutic applications. It is characterized by its ability to alleviate various types of pain and inflammation, making it a valuable component in traditional medicine.

Uses

Used in Traditional Medicine:
CNIDILIN is used as a therapeutic agent for treating various conditions such as headache, toothache, abscess, furunculosis, and acne. Its effectiveness in alleviating pain and reducing inflammation makes it a popular choice for these applications.
Used in Pain Management:
CNIDILIN is utilized as an analgesic agent, particularly for headache and toothache. Its ability to reduce pain and inflammation makes it a viable option for managing these common ailments.
Used in Dermatology:
In the field of dermatology, CNIDILIN is used as a treatment for skin conditions such as abscess, furunculosis, and acne. Its anti-inflammatory and pain-relieving properties contribute to its effectiveness in addressing these skin issues.
Used in Herbal Medicine:
CNIDILIN is also employed in herbal medicine as a key ingredient in various formulations designed to target pain and inflammation. Its presence in Radix Angelicae dahuricae makes it a valuable addition to herbal remedies for a range of health concerns.

Upstream product

• 14348-23-3 5,8-dihydroxypsoralen 
• 483-36-3 furo<3,2-g><1>benzopyran-4,7,9-trione 
• 298-81-7 9-methoxy-7H-furo[3,2-g][1]benzopyran-7-one 
• 2009-24-7 8-hydroxypsoralen 
• 49739-62-0 isoimperatorin 
• 74-88-4 methyl iodide 

Related news

In vitro permeability analysis, pharmacokinetic and brain distribution study in mice of imperatorin, isoimperatorin and CNIDILIN (cas 14348-22-2) in Radix Angelicae Dahuricae08/03/2019

Coumarins are important constituents of Radix Angelicae Dahuricae, a well-known traditional Chinese medicine possess several known bioactivities with potentials in the treatment of central nervous system diseases. By using an HPLC–MS/MS method, we analyzed the in vivo plasma and brain pharmacok...detailed

Tentative identification of new metabolites of CNIDILIN (cas 14348-22-2) by liquid chromatography–mass spectrometry08/02/2019

Cnidilin is one of the major bioactive constituents of Radix Angelicae dahuricae. The present study was designed to characterize and interpret the structures of metabolites in rats after oral administration of cnidilin at a dose of 48 mg/kg body weight. Metabolite identification was accomplished...detailed

Relevant articles and documents

Structure-activity relationships for naturally occurring coumarins as β-secretase inhibitor

The present study was demonstrated to evaluate the effects of naturally occurring coumarins (NOCs) including simple coumarins, furanocoumarins, and pyranocoumarins on the inhibition of β-secretase (BACE1) activity. Of 41 NOCs examined, some furanocoumarins inhibited BACE1 activity, but simple coumarins and pyranocoumarins did not affect. The most potent inhibitor was 5-geranyloxy-8-methoxypsoralen (31), which has an IC50 value of 9.9 μM. Other furanocoumarin derivatives, for example, 8-geranyloxy-5- methoxypsoralen (35), 8-geranyloxypsoralen (24), and bergamottin (18) inhibited BACE1 activity, with the IC50 values 25.0 μM. Analyses of the inhibition mechanism by Dixon plots and Cornish-Bowden plots showed that compounds 18, 31 and 35 were mixed-type inhibitor. The kinetics of inhibition of BACE1 by coumarins 24 was non-competitive inhibitors.